THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE RESTRICTED AND ARE NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION.

UNLESS OTHERWISE INDICATED, CAPITALISED TERMS IN THIS ANNOUNCEMENT HAVE THE MEANINGS GIVEN TO THEM IN THE DEFINITIONS SECTION OF THE CIRCULAR TO SHAREHOLDERS OF THE COMPANY DATED 22 OCTOBER 2025.

Oxford BioDynamics PLC

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Result of General Meeting

Director/PDMR Dealings

7 November 2025 - Oxford BioDynamics PLC (AIM: OBD), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform announces that the resolutions proposed at the General Meeting of the Company, held earlier today, were duly passed.

Further to the passing of the resolutions at the General Meeting, applications have been made for 2,333,333,326 new ordinary shares of £0.001 each in the capital of the Company ("Ordinary Shares"), to be issued pursuant to the fundraising announced on 22 October 2025 (the "Fundraising"), to be admitted to trading on AIM, comprising: (i) 208,333,332 Placing Shares (the "VCT/EIS Placing Shares"); and (ii) 2,093,333,329 Placing Shares (the "General Placing Shares") and 31,666,665 Subscription Shares.

It is expected that admission of the VCT/EIS Placing Shares ("VCT/EIS Admission") will take place, and trading in the VCT/EIS Placing Shares will commence at 8.00 a.m. on 10 November 2025 and that admission of the General Placing Shares and the Subscription Shares ("General Admission") will take place, and trading in the General Placing Shares and the Subscription Shares will commence at 8.00 a.m. on 11 November 2025.

Following VCT/EIS Admission, the Company's issued ordinary share capital and total voting rights will consist of 2,165,910,973 Ordinary Shares. Following General Admission, the Company's issued ordinary share capital and total voting rights will consist of 4,290,910,967 Ordinary Shares. These figures should be used by shareholders as the denominator for the calculation by which they determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

The total new Ordinary Shares subscribed for pursuant to the Fundraising by the Directors and PDMRs who are participating in the Fundraising, are set out below:

¹ Stephen Diggle's beneficial shareholding is held through the Vulpes Life Sciences Fund and Vulpes Testudo Fund, which are controlled by him.

Capitalised terms used but not otherwise defined in this announcement have the meanings set out in the circular published on 22 October 2025.

For more information:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

Director/PDMR Dealings